Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Acitretin therapy in keratinization disorders].

R J van Dooren-Greebe1, P C van de Kerkhof, P M Steijlen

  • 1Sint-Radboudziekenhuis, afd. Dermatologie, Nijmegen.

Nederlands Tijdschrift Voor Geneeskunde
|October 13, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Variants in the L12 linker domain of KRT10 are causal to atypical epidermolytic ichthyosis.

The Journal of dermatology·2024
Same author

HRAS mosaicism in linear palmoplantar keratoderma.

Journal of the European Academy of Dermatology and Venereology : JEADV·2023
Same author

Expanding the molecular and clinical spectrum of autosomal recessive congenital ichthyosis caused by pathogenic variants in NIPAL4 and PNPLA1 and evaluation of novel therapeutic interventions.

Journal of the European Academy of Dermatology and Venereology : JEADV·2023
Same author

Topical treatment of psoriasis: questionnaire results on topical therapy as long-term continuous treatment and use on specific body sites.

The Journal of dermatological treatment·2020
Same author

Schnitzler's syndrome - a novel hypothesis of a shared pathophysiologic mechanism with Waldenström's disease.

Orphanet journal of rare diseases·2019
Same author

Recessive mosaicism in ABCA12 causes blaschkoid congenital ichthyosiform erythroderma.

The British journal of dermatology·2019

Acitretin, a new oral retinoid, offers a safer alternative to etretinate for keratinization disorders due to its shorter half-life and reduced teratogenic potential. Therapeutic results and side effects are comparable to etretinate.

Area of Science:

  • Dermatology
  • Pharmacology

Context:

  • Disorders of keratinization require effective systemic treatments.
  • Oral retinoids like etretinate have advanced treatment but pose risks.
  • Acitretin represents a newer generation of oral retinoids.

Purpose:

  • To evaluate the therapeutic efficacy and side effect profile of acitretin in patients with disorders of keratinization.
  • To compare acitretin with etretinate regarding treatment outcomes and safety.

Summary:

  • Acitretin, with a significantly shorter half-life (2 days) than etretinate (100 days), was investigated in 36 patients with keratinization disorders.
  • Clinical efficacy and observed side effects of acitretin were found to be similar to those of etretinate.
  • Acitretin offers advantages in managing teratogenic potential and requires a shorter contraception period post-therapy (2 months vs. 2 years).

Related Experiment Videos

Impact:

  • Acitretin has replaced etretinate in the Netherlands since December 1989, indicating clinical preference.
  • The findings support acitretin as a viable and potentially safer option for managing keratinization disorders.
  • This study contributes to understanding the clinical utility of acitretin in dermatological practice.